Sun pharma company and also the Pune-based National Institute of medical specialty (NIV), an establishment of the Indian Council of Medical research (ICMR), have signed a agreement for testing pharmaceutical, biological and chemical entities developed by Sun pharma company against zika, chikungunya and dengue fever viruses. Sun pharma company may offer drug molecules to NIV for the testing of disease zika, chikungunya and dengue fever in model systems. Candidate molecules with encouraging information can then be taken forward for industrial development.
“Our agreement with NIV for developing the medication against zika, dengue fever and chikungunya is an element of our broader commitment for developing new and improved vaccines and medicines against arboviruses that are of serioushealth importance to Republic of India and remainder of the globe. Our call to partner with NIV was created following intensive due diligence and consultations on existing programs globally,” commented Kirti Ganorkar, executive VP & head, international business development, Sun Pharma.
Sun pharma company and NIV aim to market discovery sciences, translational health analysis and development of medical merchandise, that is in synchronize with the direction provided by Government of Republic of India’s build In India initiative. Sun Pharma’s agreement with NIV follows its MoU with ICMR for conducting joint research project and innovation for testing of medication, biosimilars and vaccines and illness management and elimination programs.
Sun pharma company and NIV can work along to retort to important and rising public health threats in Republic of India and remainder of the globe owing to zika, chikungunya and dengue fever viruses. These are arboviral diseases that have quickly spreed-ed across planet within last decade, and have usually diode to large-scale endemic outbreaks in tropical and sub-tropical countries.
While these infectious agent diseases are transmitted to humans by infected aedes mosquitoes, zika and chickungunya viruses are genetically connected. These 3 diseases create major public health concern owing tolack of any vaccine or any specific therapeutic medication to treat or cure. The patients ar given symptomatic treatment.
Dr Devendra Mourya, director, NIV, said, “Dengue and chikungunya are major public ill health in Republic of India like most of the tropical and semitropical countries. Recently, fast unfold of zika virus across the globe has sidethreat to the list of arthropod genus borne infections. sadly, nevertheless no effective antivirals and vaccines aroffered for these infections. Our agreement with Sun pharma company aims to seek out an answer to those unmet desires.”
National Institute of medical specialty is an apex institute within the country for polishing off analysis on infectious agent infections beneath the Indian Council of Medical analysis. NIV has developed comprehensive infrastructure facilities like tissue culture, medicine, organic chemistry, immunology, and medical biology for analysis in arbovirology. it’s recognised because the World Health Organization (WHO) regional collaborating centre for reference and analysis on arboviruses, contagious disease and rubeola furthermore as national reference centre for liver disease, vertebrate contagious disease and rising infectious diseases.